Key result
Elevated C-reactive protein-triglyceride-glucose index (CTI > 1.98) was independently associated with an increased risk of all-cause mortality (HR 1.697) in patients with chronic heart failure.
Why the study?
The prognostic value of the C-reactive protein-triglyceride-glucose index for all-cause mortality across the ejection fraction spectrum in chronic heart failure was unclear.
Does an elevated C-reactive protein-triglyceride-glucose index (CTI) predict all-cause mortality in patients with chronic heart failure?
Cohort (n=1,130)
No
Does an elevated C-reactive protein-triglyceride-glucose index (CTI) predict all-cause mortality in patients with chronic heart failure?
Hazard Ratio: 1.697 (95% CI 1.522–1.891)
p-value: p=<0.001
The C-reactive protein-triglyceride-glucose index (CTI) may serve as a useful independent prognostic biomarker for risk stratification of all-cause mortality in patients with chronic heart failure.
Objective The C-reactive protein-triglyceride-glucose index (CTI) is a novel biomarker integrating inflammation and insulin resistance. Its prognostic value for all-cause mortality in patients with chronic heart failure (CHF) across the ejection fraction (EF) spectrum remains unclear. Methods Patients were categorized into low- and high-CTI groups based on a restricted cubic spline-derived cutoff. Kaplan–Meier curves were used to compare survival, and Cox proportional hazards models were used to assess the association between CTI and all-cause mortality. Receiver operating characteristic (ROC) analysis and subgroup analyses were performed. Results A total of 1,130 patients with CHF were included. Kaplan–Meier survival analysis showed that patients with elevated CTI levels had a significantly higher risk of all-cause mortality compared to those with lower CTI levels. Multivariable-adjusted Cox proportional hazards analysis further confirmed that CTI levels were independently associated with increased all-cause mortality. Subgroup analysis demonstrated that elevated CTI levels were associated with higher all-cause mortality in patients with heart failure with reduced ejection fraction (HFrEF) and mildly reduced ejection fraction (HFmrEF). Conclusions CTI is an independent prognostic marker for all-cause mortality in patients with CHF across different EF subtypes and may serve as a useful risk stratification biomarker.
No takes yet. Share an insight, caveat, or question.
L et al. (2026) conducted a cohort in Chronic heart failure (n=1,130). Elevated C-reactive protein-triglyceride-glucose index (CTI > 1.98) vs. Low CTI (CTI ≤ 1.98) was evaluated on All-cause mortality (HR 1.697, 95% CI 1.522-1.891, p=<0.001). Elevated C-reactive protein-triglyceride-glucose index (CTI > 1.98) was independently associated with an increased risk of all-cause mortality (HR 1.697) in patients with chronic heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: